United Therapeutics (UTHR) CEO’s 10b5-1 plan sale covers 9,500 shares
Filing Impact
Filing Sentiment
Form Type
4
Rhea-AI Filing Summary
UNITED THERAPEUTICS Corp Chairperson & CEO Martine Rothblatt reported an exercise-and-sale transaction in company stock. She exercised stock options to acquire 9,500 shares of common stock at an exercise price of $146.03 per share and sold 9,500 shares in multiple open-market trades on May 8, 2026 at weighted average prices generally between the high $560s and low $570s per share. The filing states these transactions were made under a pre-arranged Rule 10b5-1 trading plan adopted on November 7, 2025, which is scheduled to continue until the earlier of the exercise of 1,734,410 stock options expiring on March 17, 2027, or December 31, 2026. After these transactions, Rothblatt directly holds 40,513 shares of common stock and has additional indirect holdings through various family trusts and her spouse.
Positive
- None.
Negative
- None.
Insider Trade Summary 10b5-1
Net Seller: 9,500 shares ($5,367,044)
Net Sell
17 txns
Insider
ROTHBLATT MARTINE A
Role
Chairperson & CEO
Sold
9,500 shs ($5.37M)
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Stock Option | 9,500 | $0.00 | -- |
| Exercise | Common Stock | 9,500 | $146.03 | $1.39M |
| Sale | Common Stock | 1,126 | $562.083 | $633K |
| Sale | Common Stock | 2,022 | $563.0571 | $1.14M |
| Sale | Common Stock | 1,864 | $564.002 | $1.05M |
| Sale | Common Stock | 1,983 | $564.7694 | $1.12M |
| Sale | Common Stock | 705 | $565.9862 | $399K |
| Sale | Common Stock | 319 | $567.2088 | $181K |
| Sale | Common Stock | 360 | $568.159 | $205K |
| Sale | Common Stock | 106 | $569.6123 | $60K |
| Sale | Common Stock | 495 | $570.2186 | $282K |
| Sale | Common Stock | 520 | $571.6638 | $297K |
| holding | Common Stock | -- | -- | -- |
| holding | Common Stock | -- | -- | -- |
| holding | Common Stock | -- | -- | -- |
| holding | Common Stock | -- | -- | -- |
| holding | Common Stock | -- | -- | -- |
Holdings After Transaction:
Stock Option — 24,788 shares (Direct, null);
Common Stock — 50,013 shares (Direct, null);
Common Stock — 166 shares (Indirect, by Spouse)
Footnotes (1)
- This exercise of stock options and sale of the resulting shares of common stock was pursuant to a pre-arranged 10b5-1 trading plan adopted by the reporting person on November 7, 2025. This plan will continue until the earlier of: (a) the exercise of 1,734,410 stock options, all of which expire on March 17, 2027; or (b) December 31, 2026. This transaction was executed in multiple trades at prices ranging from $569.99 to $570.75. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. This transaction was executed in multiple trades at prices ranging from $571.32 to $571.99. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Shares held in family trusts as to which the Reporting Person shares investment power and the Reporting Person and/or immediate family members are beneficiaries. Shares held in family trusts as to which the Reporting Person's spouse is sole trustee and sole beneficiary or co-trustee and settlor with power to revoke. Shares held in family trusts as to which the Reporting Person's spouse shares investment power and the Reporting Person and/or immediate family members are beneficiaries. Shares held in family trusts as to which the Reporting Person is sole trustee and sole beneficiary or co-trustee and settlor with power to revoke. This transaction was executed in multiple trades at prices ranging from $561.45 to $562.43. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. This transaction was executed in multiple trades at prices ranging from $562.46 to $563.45. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. This transaction was executed in multiple trades at prices ranging from $563.46 to $564.45. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. This transaction was executed in multiple trades at prices ranging from $564.47 to $565.46. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. This transaction was executed in multiple trades at prices ranging from $565.53 to $566.26. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. This transaction was executed in multiple trades at prices ranging from $566.81 to $567.80. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. This transaction was executed in multiple trades at prices ranging from $567.86 to $568.84. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. This transaction was executed in multiple trades at prices ranging from $568.985 to $569.93. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
Key Figures
Shares sold: 9,500 shares
Options exercised: 9,500 options
Option exercise price: $146.03 per share
+5 more
8 metrics
Shares sold
9,500 shares
Open-market sales of common stock on May 8, 2026
Options exercised
9,500 options
Stock options exercised into common stock on May 8, 2026
Option exercise price
$146.03 per share
Exercise price for 9,500 stock options
Example sale price
$571.6638 per share
One reported weighted average sale price for 520 shares
Direct holdings after transaction
40,513 shares
Common stock directly held following May 8, 2026 trades
Indirect trust holding example
324,443 shares
Common stock held indirectly in a family trust
Remaining option balance (reported line)
24,788 options
Stock options total following derivative transaction entry
10b5-1 plan end condition
1,734,410 options or Dec 31, 2026
Plan ends after exercising 1,734,410 options or by that date
Key Terms
Rule 10b5-1 trading plan, stock options, weighted average price, family trusts, +2 more
6 terms
Rule 10b5-1 trading plan financial
"This exercise of stock options and sale ... was pursuant to a pre-arranged 10b5-1 trading plan..."
A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.
stock options financial
"This exercise of stock options and sale of the resulting shares of common stock..."
Stock options are agreements that give a person the right to buy or sell a company's stock at a specific price within a certain time frame. They are often used as a reward or incentive, similar to a coupon that can be used later if the stock price rises, allowing the holder to make a profit.
weighted average price financial
"The price reported above reflects the weighted average price."
Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.
family trusts financial
"Shares held in family trusts as to which the Reporting Person shares investment power..."
exercise or conversion of derivative security financial
"Exercise or conversion of derivative security"
open-market sale financial
"Sale in open market or private transaction"
An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.
FAQ
What insider transactions did UTHR CEO Martine Rothblatt report on May 8, 2026?
Martine Rothblatt reported exercising stock options for 9,500 United Therapeutics shares and selling 9,500 shares in open-market trades on May 8, 2026. The trades occurred at weighted average prices in the high $560s to low $570s per share.
Was the UTHR CEO’s May 2026 stock sale part of a Rule 10b5-1 plan?
Yes, the United Therapeutics CEO’s option exercise and related share sales were executed under a pre-arranged Rule 10b5-1 trading plan adopted on November 7, 2025. The plan governs ongoing option exercises until specified limits or December 31, 2026.
What was the exercise price of the UTHR stock options exercised by the CEO?
The exercised United Therapeutics stock options had an exercise price of $146.03 per share for 9,500 underlying common shares. These options are part of a larger grant expiring on March 17, 2027, referenced in the Rule 10b5-1 trading plan description.
At what prices did the UTHR CEO’s May 8, 2026 stock sales occur?
The reported United Therapeutics share sales on May 8, 2026 were executed in multiple trades at weighted average prices around the mid to high $560s and low $570s per share. Footnotes note detailed trade price ranges and offer to provide full breakdowns on request.